What question did this study set out to answer?

The study investigates the role of BCL-2 family proteins as sensitizers to 5-Azacytidine in myeloid malignancies.

January 23, 2014LeukemiaOpen Access

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies BCL-2 family proteins influencing 5-Azacytidine response in myeloid malignancies, suggesting new treatment strategies.

The study investigates the role of BCL-2 family proteins as sensitizers to 5-Azacytidine in myeloid malignancies.
Performed RNA-interference drug modifier screens to identify BCL-2 family proteins.
Conducted siRNA silencing of BCL-XL and MCL-1 to assess synergy with 5-Azacytidine.
Utilized BH3 profiling to predict clinical response in patient samples.
ABT-737 enhanced 5-Azacytidine activity across primary AML, MDS, and MPN specimens.
Silencing of MCL-1 and BCL-XL increased the effect of ABT-199.
BH3 profiling successfully discriminated between responders and non-responders to 5-Azacytidine.

Bogenberger et al. (2014) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial identifies BCL-2 family proteins influencing 5-Azacytidine response in myeloid malignancies, suggesting new treatment strategies.